| Objective :To explore the safety and efficacy of retrexed combined with cisplatin(recombinant human vascular endostatin)in the treatment of gastric cancer patients with peritoneal effusion.Methods:60 cases of gastric cancer with malignant ascites were randomly divided into 2 groups: 30 cases in the experimental group were given retrexed combined with grace regimen chemotherapy,and 30 cases in the control group were treated with cisplatin combined with grace regimen chemotherapy.The two groups were treated with 3 intraperitoneal chemotherapy for 1 courses and 2 courses of treatment.After 2 courses of treatment,short-term efficacy,adverse reactions and quality of life were evaluated.Results:The treatment efficiency(CR+PR)was 53.33% in the experimental group and 40% in the control group(CR+PR).The data of the two groups showed that the difference was not obvious and the comparison was not statistically significant(P > 0.05).In the incidence of side effects,the side effects of the two groups were less than those in the control group,and there were no statistical differences in platelet,hemoglobin,aminotransferase,alkaline phosphatase and pain(P > 0.05),but the degree of leukocyte reduction and gastrointestinal discomfort in the two groups were poor.The difference was statistically significant(P < 0.05).Quality of life of the two groups of patients have improved the quality of life,with statistical difference(P < 0.05),the overall improvement rate of the experimental group was 60%,the overall improvement rate of the control group was 26.67%,the improvement rate of the experimental group was better than the control group,the two groups had statistical significance(P < 0.05).Conclusion:Retrexed combined with degree of grace in the treatment of gastric cancer with malignant ascites can improve the patient's clinical symptoms and quality of life,and it is well tolerated and safe.It is worthy of further clinical study. |
PDF Full Text Request